Liver Diseases  >>  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
NCT00435812 / 2006-006743-31: Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine

Completed
3
2428
Canada, Europe
HEPLISAV and/or Placebo, HEPLISAV, Hepatitis B vaccine (recombinant), adjuvanted, Engerix-B, Hepatitis B vaccine (recombinant)
Dynavax Technologies Corporation
Hepatitis B
02/08
03/08
NCT01195246 / 2010-019633-10: Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

Completed
3
155
Europe
HEPLISAV, Hepatitis B Vaccine (Recombinant), Adjuvanted, Engerix-B, Hepatitis B Vaccine (Recombinant), Fendrix
Dynavax Technologies Corporation
End Stage Renal Disease
02/12
08/12

Download Options